Myriad Genetics to Present at Two Upcoming Healthcare Conferences
February 27 2018 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, announced today that
Mark C. Capone, president and CEO, is scheduled to present at two
upcoming investor conferences. On March 13, 2018, Mr. Capone will
present at the 38th annual Cowen Healthcare Conference in Boston,
Massachusetts at 8:40 a.m. ET. On March 14, 2018, Mr. Capone will
present at the Barclays Global Healthcare Conference in Miami,
Florida at 2:35 p.m. ET.
The presentations will be available to interested
parties through a live audio webcast accessible through a link in
the investor information section of Myriad’s website at
www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized
medicine company dedicated to being a trusted advisor transforming
patient lives worldwide with pioneering molecular
diagnostics. Myriad discovers and commercializes molecular
diagnostic tests that: determine the risk of developing disease,
accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight,
riskScore and Prolaris are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: |
|
Ron Rogers |
|
Investor Contact: |
|
Scott Gleason |
|
|
(801) 584-3065 |
|
|
|
(801) 584-1143 |
|
|
rrogers@myriad.com |
|
|
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024